Mylan CEO Heather Bresch will address the EpiPen pricing uproar at Forbes Health Summit Dec. 1, though she refused to testify before the Senate Judiciary Committee at a now-canceled Nov. 30 Senate hearing. Sen. Charles Grassley (R-IA) urged her to appear before the committee, but Bresch refused. CMS and the U.S. Department of Justice also declined to send officials to testify. In a statement sent to STAT's Pharmalot blog, Grassley said the billions of dollars spent on drugs oblige pharmaceutical...